ArticleFrontiers in medicine2025
Characterization of sarcoidosis at a combined rheumatology-pulmonary clinic.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The treatment landscape for sarcoidosis remains poorly defined, as there is no standardized approach to management. This study aims to characterize a cohort of sarcoidosis patients in a combined rheumatology-pulmonary clinic with regard to organ involvement and medications used. To our knowledge, this will be the first published manuscript to detail such a population, providing critical insight to inform and improve the care of patients with sarcoidosis in the multidisciplinary setting. Methods: This study was a retrospective chart review of sarcoidosis patients seen at the collaborative rheumatology-pulmonology clinic at Oregon Health & Science University during the first 5 years following the clinic's inception (October 2018 to October 2023). Using ICD-10 diagnostic codes, 219 patient charts were identified. Of these, 37 were excluded for not meeting inclusion criteria, resulting in 182 charts eligible for data analysis. We used Excel spreadsheets to analyze our data. Results: 119 (65.3%) of patients in our data base had multi-organ involvement of sarcoidosis. Treatment patterns differed between patients with multi-organ sarcoidosis and those with single-organ or isolated lung/lymph node involvement. Notable differences (in prescribing) were observed among patients with cardiac and neurologic manifestations. Additionally, patients with cardiac involvement demonstrated distinct demographic characteristics, including differences in age and SRY carrier status, when compared to the broader cohort. Conclusion: Our data highlights the complexity and heterogeneity of sarcoidosis seen in a combined rheumatology-pulmonary clinic. Further research is required to prospectively evaluate various pharmacologic treatment in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.